Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RCT2100 in Healthy Participants and Cystic Fibrosis
NCT06237335Phase 2Active, not recruiting
- Sponsor
- ReCode Therapeutics
- Start
- Feb 2024
- Primary completion
- Nov 2026
- Countries
- 5
01
Overview
A Phase 2 trial of RCT2100 in cystic fibrosis (CF), sponsored by ReCode Therapeutics. Started Feb 2024; status: active, not recruiting.
02
Drugs
RCT2100
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT06237335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06237335.